Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies

Minerva Stomatol. 2002 Sep;51(9):405-9.

Abstract

Background: Alpha-lipoic acid (ALA) is a potent antioxidant mitochondrial coenzyme, trometamol salt of thioctic acid, shown in clinical studies to be neuroprotective and in a preliminary study to have an effect on the symptomatology of Burning Mouth Syndrome (BMS).

Methods: We were interested in extending our studies as to whether alpha-lipoic acid might improve the symptomatology in BMS and therefore carried out a larger open controlled clinical study on the effects of alpha-lipoic acid on BMS symptomatology.

Results: We have examined the effects on 4 groups of 20 patients with BMS of ALA, compared with bethanecol, Biotene and placebo, and found ALA of remarkable benefit with minimal adverse effects.

Conclusions: These results suggest that double-blind randomized controlled multicenter studies of ALA are indicated.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Bethanechol / therapeutic use
  • Burning Mouth Syndrome / drug therapy*
  • Cohort Studies
  • Drug Combinations
  • Female
  • Glucose Oxidase / therapeutic use
  • Humans
  • Lactoperoxidase / therapeutic use
  • Male
  • Middle Aged
  • Mouthwashes / therapeutic use
  • Muramidase / therapeutic use
  • Neuroprotective Agents / therapeutic use*
  • Thioctic Acid / therapeutic use*
  • Treatment Outcome
  • Xylitol / therapeutic use

Substances

  • Biotene
  • Drug Combinations
  • Mouthwashes
  • Neuroprotective Agents
  • Bethanechol
  • Thioctic Acid
  • Glucose Oxidase
  • Lactoperoxidase
  • Muramidase
  • Xylitol